It is therefore not clear whether an agonist or antagonist of chemerin action might be useful for the treatment of T2DM and the contribution of chemerin to the pathology of obesity and T2DM remains elusive. Here, RARRES2 is linked to obesity due to melanocortin 4 receptor deficiency.